New drug interaction study aims to keep sickle cell patients safe
NCT ID NCT06813924
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This completed Phase 1 study in 37 healthy adults tested whether a new drug called etavopivat affects how the body processes five common medicines: digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. Participants took etavopivat daily for 10 days along with single doses of each other drug. The goal was to see if etavopivat changes the levels of these medicines in the blood, which could help guide safe dosing for future patients with sickle cell disease or thalassemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS SICKLE CELL DISEASE, THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ICON-Salt Lake City
Salt Lake City, Utah, 84124, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etavopivat
What this could lead to
If successful, this study could help doctors understand how to safely combine etavopivat with other common medicines in future treatments for sickle cell disease or thalassemia.
What could go wrong
This is an early-stage study in healthy volunteers, not patients. Results may not fully predict how the drug interacts in people with the actual diseases.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.